Tonix Pharmaceuticals Holding (TNXP) Return on Capital Employed (2011 - 2026)
Tonix Pharmaceuticals Holding's (TNXP) quarterly Return on Capital Employed came in at 63.55% in Q1 2026, up 1573.0% year-on-year from 3.8% in Q1 2025, and down 18.29% quarter-over-quarter from 53.73% in Q4 2025.
Tonix Pharmaceuticals Holding (TNXP) Return on Capital Employed (2011 - 2026) Analysis & Trends
Tonix Pharmaceuticals Holding's Return on Capital Employed history runs 16 years deep, the most recent figure standing at 63.55% for Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 1573.0% year-over-year to 63.55% in Q1 2026; TTM through Mar 2026 was 63.55%, a 1573.0% increase from a year earlier, with the FY2025 full-year figure at 66.44%, up 3095.0% from the prior year.
- Return on Capital Employed slipped to 63.55% in Q1 2026 per TNXP's latest filing, from 53.73% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 41.78% in Q2 2022 and bottomed at 209.81% in Q3 2024.
- The 5-year median for Return on Capital Employed is 63.55% (2026), against an average of 83.52%.
- Across the five-year window, Return on Capital Employed tumbled 11587 bps in 2024 and jumped 15957 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 51.9% in 2022, then plunged by 78 bps to 92.49% in 2023, then plunged by 34 bps to 123.56% in 2024, then jumped by 57 bps to 53.73% in 2025, then retreated by 18 bps to 63.55% in 2026.
- Per Business Quant, the three latest TNXP Return on Capital Employed figures stand at 63.55% (Q1 2026), 53.73% (Q4 2025), and 50.23% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -68.84% |
| 10 | Tonix Pharmaceuticals Holding | 142.07 Mn | 142.07 Mn | 5.30 Mn | -63.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -63.55% |
| Dec 31, 2025 | -53.73% |
| Sep 30, 2025 | -50.23% |
| Jun 30, 2025 | -48.16% |
| Mar 31, 2025 | -79.29% |
| Dec 31, 2024 | -123.56% |
| Sep 30, 2024 | -209.81% |
| Jun 30, 2024 | -190.81% |
| Mar 31, 2024 | -85.06% |
| Dec 31, 2023 | -92.49% |
| Sep 30, 2023 | -93.93% |
| Jun 30, 2023 | -82.95% |
| Mar 31, 2023 | -63.15% |
| Dec 31, 2022 | -51.90% |
| Sep 30, 2022 | -44.23% |
| Jun 30, 2022 | -41.78% |
| Mar 31, 2022 | -45.18% |
| Dec 31, 2021 | -44.79% |
| Sep 30, 2021 | -42.04% |
| Jun 30, 2021 | -41.13% |